Conformation-Specific Antibodies for Alpha-Synuclein Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for neurodegenerative diseases such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy lack reliable and disease-specific biomarkers, making early and precise diagnosis challenging due to the misfolding and aggregation of α-synuclein proteins.
Innovation Solution
Development of conformation-specific monoclonal antibodies that target α-synuclein aggregates, allowing for the detection and assessment of disease-related α-synuclein pathology in various biological samples, including brain, cerebrospinal fluid, blood plasma, saliva, urine, skin, nasal swabs, and feces, using specific antibody sequences and immunoassay kits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional diagnostic methods are used for neurodegenerative diseases, then general clinical criteria can be applied, but reliable and disease-specific biomarkers are lacking, making precise diagnosis difficult
Solution Approach 1:
The patent changes the detection parameter from general clinical criteria to specific conformational states of α-synuclein aggregates. By targeting the unique folded conformation of aggregated α-synuclein rather than the protein in general, the assay achieves disease-specific biomarker detection with high precision for synucleinopathies
Solution Approach 2:
The patent replaces general clinical assessment mechanisms with a molecular-level immunoassay mechanism. Using conformation-specific monoclonal antibodies that recognize the specific three-dimensional structure of aggregated α-synuclein, the system substitutes macroscopic clinical criteria with microscopic molecular detection, enabling precise biomarker identification
2Measurement precision
If α-synuclein aggregates are detected in biological fluids, then disease-specific biomarkers can be identified, but the complexity of the immunoassay system increases
Solution Approach 1:
The patent segments the detection system into distinct functional components: conformation-specific monoclonal antibodies for recognizing aggregated α-synuclein, appropriate biological fluid samples, and immunoassay platforms. This segmentation allows each component to be optimized independently while maintaining overall system precision
Solution Approach 2:
The patent uses conformation-specific monoclonal antibodies as intermediary molecules that bridge the gap between the target α-synuclein aggregates and the detection system. These antibodies serve as mediators that specifically recognize and bind to the conformational epitopes of aggregated α-synuclein, enabling precise detection without requiring direct interaction with the complex aggregate structures
3Reliability
If conformation-specific monoclonal antibodies are used to target α-synuclein aggregates, then disease-specific detection is achieved, but the development and validation process becomes more complex
Solution Approach 1:
The patent performs preliminary characterization of α-synuclein aggregate conformations and identifies specific conformational epitopes before developing the full assay system. This preliminary action allows for the rational design and selection of conformation-specific monoclonal antibodies that target these pre-identified structural features, streamlining the subsequent assay development process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The diagnostic assays provide quantitative, disease-specific, and highly sensitive analysis of α-synuclein oligomers, enabling early and precise diagnosis, monitoring of disease progression, and guiding targeted therapeutics, thereby improving patient care and treatment outcomes.
Implementation Method 1
The pathogenesis of Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) is closely associated with the misfolding and aggregation of the protein α-synuclein into toxic insoluble fibrils in the affected regions of the brain.
Data Source
AI summary
Antibodies and diagnostic assays for detecting synucleinopathies are provided. The assay is specific and compatible with different biological samples (brain, cerebrospinal fluid, blood, saliva, urine, skin, nasal swabs, or feces).